Japan, Jan. 20 -- BAYER HEALTHCARE LLC has got intellectual property rights for 'COMBINATION USE OF REGORAFENIB AND PD-1/PD-L1 (2) INHIBITORS FOR CANCER TREATMENT.' Other related details are as follows:
Application Number: JP,2024-066115
Category (FI): A61P43/00,121,A61K39/395@D,A61P35/04,A61P43/00,105,A61K45/00,A61P35/00,A61K39/395@N,A61K31/44
Stage: Grant (IP right granted following substantive examination.)
Filing Date: April 16, 2024
Publication Date: July 17, 2024
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
